Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited reported at the ENCALS conference that their Phase 1 MEND study of monepantel (MPL) showed a significant survival benefit for ALS patients compared to untreated controls. Highlighted results included improved ALSFRS-R scores and a 91% reduced risk of death. The company is preparing for a Phase 2/3 STRIKE study, aiming for potential accelerated FDA approval by 2026.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
